Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2003 Apr 1;8(7):307-15.

Potential for proteasome inhibition in the treatment of cancer.

Author information

1
Millennium Pharmaceuticals, 35 Landsdowne Street, Cambridge, MA 02139, USA. jadams@mpi.com

Abstract

Proteasome inhibition is a new approach to treating cancer. Proteasome inhibitors specifically induce apoptosis in cancer cells, but most proteasome inhibitors are not suitable for clinical development. Peptide boronates overcome the shortcomings of earlier generation proteasome inhibitors, and bortezomib (VELCADE; formerly PS-341) is the first peptide boronate to enter clinical trials. Preclinical studies of bortezomib have demonstrated antitumor activity in a variety of tumor types. Phase I trials provided evidence of manageable toxicities and support a twice-weekly dosing regimen now being examined in a Phase III study.

Comment in

PMID:
12654543
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center